Literature DB >> 25987025

Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Factor in Patients with Non-metastatic Renal Cell Carcinoma.

Ru-Min Wen1, Yi-Jing Zhang, Sha Ma, Ying-Li Xu, Yan-Su Chen, Hai-Long Li, Jin Bai, Jun-Nian Zheng.   

Abstract

BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) is a strong predictor of mortality in patients with colorectal, lung, gastric cancer, pancreatic and metastatic renal cell carcinoma. We here evaluated whether preoperative NLR is an independent prognostic factor for non-metastatic renal cell carcinoma (RCC).
MATERIALS AND METHODS: Data from 327 patients who underwent curative or palliative nephrectomy were evaluated retrospectively. In preoperative blood routine examination, neutrophils and lymphocytes were obtained. The predictive value of NLR for non-metastatic RCC was analyzed.
RESULTS: The NLR of 327 patients was 2.72±2.25. NLR <1.7 and NLR ≥1.7 were classified as low and high NLR groups, respectively. Chi-square test showed that the preoperative NLR was significantly correlated with the tumor size (P=0.025), but not with the histological subtype (P=0.095)and the pT stage (P=0.283). Overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method. Effects of NLR on OS (P=0.007) and DFS (P=0.011) were significant. To evaluate the independent prognostic significance of NLR, multivariate COX regression models were applied and identified increased NLR as an independent prognostic factor for OS (P=0.015), and DFS (P=0.019).
CONCLUSIONS: Regarding patient survival, an increased NLR represented an independent risk factor, which might reflect a higher risk for severe cardiovascular and other comorbidities. An elevated blood NLR may be a biomarker of poor OS and DFS in patients with non-metastatic RCC.

Entities:  

Mesh:

Year:  2015        PMID: 25987025     DOI: 10.7314/apjcp.2015.16.9.3703

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Nonmetastatic Renal Cell Carcinoma: A Large, Multicenter Cohort Analysis.

Authors:  Seok-Soo Byun; Eu Chang Hwang; Seok Ho Kang; Sung-Hoo Hong; Jinsoo Chung; Tae Gyun Kwon; Hyeon Hoe Kim; Cheol Kwak; Yong-June Kim; Won Ki Lee
Journal:  Biomed Res Int       Date:  2016-11-06       Impact factor: 3.411

2.  Preoperative Lymphocyte-Monocyte Ratio Ameliorates the Accuracy of Differential Diagnosis in Non-Metastatic Infiltrative Renal Masses.

Authors:  Jang Hee Han; Young Eun Yoon; Sook Young Kim; Young In Cho; Koon Ho Rha; Young Deuk Choi; Woong Kyu Han
Journal:  Yonsei Med J       Date:  2017-03       Impact factor: 2.759

3.  Value of the preoperative neutrophil-to-lymphocyte ratio as a prognostic factor for long-term survival in postoperative esophageal squamous cell carcinoma patients.

Authors:  Guang-Wen Xu; Han-Ran Wu; Ran Xiong; Cai-Wei Li; Chang-Qing Liu; Mei-Qing Xu; Ming-Ran Xie
Journal:  Thorac Cancer       Date:  2018-10-12       Impact factor: 3.500

4.  Prognostic significance of preoperative and follow-up neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma.

Authors:  Tae Woo Kim; Jung Hwan Lee; Kang Hee Shim; Seol Ho Choo; Jong Bo Choi; Hyun Soo Ahn; Se Joong Kim; Sun Il Kim
Journal:  Investig Clin Urol       Date:  2018-11-23

5.  Targeting Cytokine Storm in COVID-19: A Role of Online Hemodiafiltration with Asymmetric Cellulose Triacetate in Maintenance Hemodialysis Patients-A Report of 10 Cases.

Authors:  José C De La Flor; Francisco Valga; Alexander Marschall; Tania Monzon; Cristina Albarracín; Elisa Ruiz; Miguel Rodeles
Journal:  Case Rep Nephrol       Date:  2021-03-12

6.  The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis.

Authors:  Ross D Dolan; Jason Lim; Stephen T McSorley; Paul G Horgan; Donald C McMillan
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.